FDA Approves Trelegy Ellipta for COPD - Medscape The FDA has approved once-daily, single inhaler triple therapy fluticasone furoate umeclidinium vilanterol (Trelegy Ellipta, GlaxoSmithKline) for patients with COPD
FDA Approves Umeclidinium and Vilanterol Combo for COPD The FDA has approved umeclidinium and vilanterol powder for inhalation for long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease
EU Approves Trelegy Ellipta for COPD - Medscape The European Commission has granted marketing authorization for fluticasone furoate umeclidinium vilanterol (Trelegy Ellipta, GlaxoSmithKline PLC and Innoviva, Inc
EU Panel Backs Umeclidinium (Incruse) for COPD - Medscape The committee favored approval of the long-acting muscarinic antagonist umeclidinium for once-daily maintenance treatment of chronic obstructive pulmonary disease in adults